Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Benjamin Louis Maughan"'
Autor:
Guru P. Sonpavde, Benjamin Louis Maughan, Bradley Alexander McGregor, Xiao X. Wei, Kerry L. Kilbridge, Richard J. Lee, Evan Y. Yu, Michael Thomas Schweizer, Robert B. Montgomery, Heather H. Cheng, Andrew Caleb Hsieh, Rohit Jain, Jaspreet S. Grewal, Cesar Pico-Navarro, Zarina Gafoor, Teresa Perschy, Petros Grivas
Publikováno v:
Cancer Immunology, Immunotherapy. 72:775-782
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b49568408392f4e14fb47518431a023
https://doi.org/10.1007/s00262-022-03274-6
https://doi.org/10.1007/s00262-022-03274-6
Autor:
Guru P, Sonpavde, Benjamin Louis, Maughan, Bradley Alexander, McGregor, Xiao X, Wei, Kerry L, Kilbridge, Richard J, Lee, Evan Y, Yu, Michael Thomas, Schweizer, Robert B, Montgomery, Heather H, Cheng, Andrew Caleb, Hsieh, Rohit, Jain, Jaspreet S, Grewal, Cesar, Pico-Navarro, Zarina, Gafoor, Teresa, Perschy, Petros, Grivas
Publikováno v:
Cancer immunology, immunotherapy : CII.
CV301 comprises recombinant poxviruses, Modified Vaccinia Ankara (MVA) and Fowlpox (FPV), encoding CEA, MUC-1, and co-stimulatory Molecules (TRICOM) ICAM-1, LFA-3, and B7-1. MVA-BN-CV301 is used for priming and FPV-CV301 is used for boosting. A Phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e373253a216f1da47a1957457457e896
https://pubmed.ncbi.nlm.nih.gov/35998004
https://pubmed.ncbi.nlm.nih.gov/35998004
Autor:
Nicolas Sayegh, Bennet Peterson, Roberto Nussenzveig, Adam Kessel, Taylor Ryan McFarland, Andrew Warren Hahn, Deepika Sirohi, Manish Kohli, Benjamin Louis Maughan, Umang Swami, Mark Yandell, Neeraj Agarwal
Publikováno v:
Molecular Cancer Therapeutics. 20:P012-P012
Background: Despite recent advancements in systemic therapy in men with mCSPC, disease remains fatal. Identification of novel genomic and clinical correlates of survival in this setting remain a significant unmet need. Methods: Newly diagnosed mCSPC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::476e27937b4debcfeaf09f89f76e5c04
https://doi.org/10.1158/1535-7163.targ-21-p012
https://doi.org/10.1158/1535-7163.targ-21-p012
Autor:
Benjamin Louis Maughan, Daniel L. Suzman, Rosa Maria Nadal, Sunakshi Bassi, Emmanuel S. Antonarakis
Publikováno v:
Journal of Clinical Oncology. 34:308-308
308 Background: Both enzalutamide and abiraterone are approved for the treatment of mCRPC, each demonstrating improved overall survival (OS) versus placebo. However, it is unclear what the optimal sequencing of these two therapies should be to maximi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ca0253346831ace404b8193c4a0d8ee
https://doi.org/10.1200/jco.2016.34.2_suppl.308
https://doi.org/10.1200/jco.2016.34.2_suppl.308